When meprobamate, best known by one of its trade names as Miltown, hit the tranquilizer market in 1955, it became a runaway bestseller because it seemed to do its work with a minimum of undesirable side effects. Now, Miltown (also marketed as Equanil) is in for a letdown. It is dropped from the U.S. Pharmacopeia new edition, which becomes effective Sept. 1.
Behind this action lies a growing disillusionment with Miltown on the part of many doctors. Some doubt that it has any more tranquilizing effect than a dummy sugar pill; others think...
To continue reading:
or
Log-In
